Theravance Biopharma (TBPH) Total Liabilities (2013 - 2026)

Theravance Biopharma (TBPH) has 14 years of Total Liabilities data on file, last reported at $181.7 million in Q1 2026.

• Total Liabilities for Q1 2026 came in at $181.7 million, up 2.32% year-over-year; the trailing twelve-month figure through Mar 2026 was $181.7 million (up 2.32% YoY), and the FY2025 annual result was $188.8 million, up 5.73% from the prior year.
• Total Liabilities fell to $181.7 million in Q1 2026 per TBPH's latest filing, from $188.8 million in the prior quarter.
• Over five years, Total Liabilities peaked at $710.6 million in Q2 2022 and troughed at $165.6 million in Q4 2022.
• A 5-year average of $244.3 million and a median of $177.6 million in 2025 frame the typical range for Total Liabilities.
• The sharpest annual moves came in 2022 and 2025: Total Liabilities sank 76.79% in 2022, then grew 19.51% in 2025.
• A 5-year view of Total Liabilities shows it stood at $165.6 million in 2022, then gained by 2.06% to $169.0 million in 2023, then advanced by 5.69% to $178.6 million in 2024, then grew by 5.73% to $188.8 million in 2025, then slipped by 3.77% to $181.7 million in 2026.
• Business Quant data shows TBPH's Total Liabilities at $181.7 million in Q1 2026, $188.8 million in Q4 2025, and $182.8 million in Q3 2025.